Celyad OncologyCLYYF 13 Days Inventory is 0.00 as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 640 Biotechnology companies, Celyad Oncology ranks worse than 99.38% on this metric.
The historical rank and industry rank for Celyad Oncology's Days Inventory or its related term are showing as below:
CLYYF'
s Days Inventory Range Over the Past 10 Years
Min: 11708.08 Med: 15366.86 Max: 19025.63
Current: 15330
During the past 13 years, Celyad Oncology's highest Days Inventory was 19025.63. The lowest was 11708.08. And the median was 15366.86.
CLYYF's Days Inventory is ranked worse than 99.38% of 640
companies
in the Biotechnology industry
Industry Median: 184.145
vs CLYYF: 15330.00
Celyad Oncology's Days Inventory
declined
from Dec. 2024 (19,938.13) to Dec. 2025 (0.00).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Celyad Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Celyad Oncology's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 36.75.
Celyad Oncology (OTCPK:CLYYF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Celyad Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Celyad Oncology's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Celyad Oncology Days Inventory Related Terms
Celyad Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Celyad Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Days Inventory of 0.00 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Celyad Oncology and its competitors. Over the past decade, Celyad Oncology's Days Inventory has ranged from 11,708.08 to 19,025.63. According to the industry distribution chart, Celyad Oncology ranks #636 out of 640 companies in the Biotechnology industry, placing it in the top 99.4%.
Is Celyad Oncology's Days Inventory too high?
Celyad Oncology's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 11,708.08 to a high of 19,025.63. Based on the distribution chart, Celyad Oncology ranks #636 out of 640 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #636 out of 640 companies for Days Inventory. This places Celyad Oncology in the lower half of its industry. The industry median Days Inventory is 184.15. Historically, Celyad Oncology's own Days Inventory has ranged from 11,708.08 to 19,025.63 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $0.25 — trading 43.2% below its estimated fair value. The current Days Inventory is 0.00. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Days Inventory is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued.
The current stock price of $0.25 is trading 43.2% below its estimated GF Value™ of $0.44.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Days Inventory: 0.00
GF Value™: $0.44 vs. price of $0.25 (43.2% below fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score
Get the complete analysis for CLYYF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
